Updated on 14.04.2026 @ 4:18 PM
Corona Remedies Limited, a fast-growing pharmaceutical company focused on women's healthcare and cardio-diabetic segments, is launching its mainboard Initial Public Offering (IPO) on December 8, 2025.
If you want to learn more about upcoming IPOs then check them out at our IPO Hub page.
The issue is a 100% Offer for Sale (OFS), with the company's promoters and investors selling shares worth up to ₹655.37 crores.
The price band has been fixed at ₹1008 to ₹1062 per share, with a minimum lot size of 14 shares.
Corona Remedies has shown strong financial performance and growth, outpacing many of its peers. If you're also exploring long-term investing alternatives, our mutual fund learning hub can guide you.
In this article, you will find Corona Remedies IPO GMP today, subscription status, allotment date, price band, and a detailed, unbiased review to help you make an informed decision.
Briefs of Corona Remedies IPO Details
- Price Band: ₹1008 – ₹1062 per share
- IPO Open / Close Dates: December 8, 2025 – December 10, 2025
- Lot Size: 14 Shares (What is the lot size, learn about key IPO terms in our glossary page which has 100+key IPO terms)
- Issue Size: 61,71,101 shares (aggregating up to ₹655.37 Crores)
- Fresh Issue / OFS: 100% Offer for Sale (OFS)
- Registrar: Bigshare Services Private Limited
- Listing Exchange: BSE & NSE
Any investor seeking help on allotment related issue, can check our detailed guide on bigshare IPO allotment useful.
What is Corona Remedies IPO GMP Today?
Check the GMP of all the IPOs at a single place: Grey market premium hub page. ( GMP is an unofficial indicator).
Listing Updates:
| Type | Issue Price | Open | Gain/loss |
| Lisiting | 1062 | 1470 | 38.4 |
Source: NSE India
What Are The Important Corona Remedies IPO Dates & Allotment Schedule?
- IPO Open & Close Date: December 8, 2025 – December 10, 2025
- Basis of Allotment Date: December 11, 2025
- Refund Initiation Date: December 12, 2025
- Credit of Shares: December 12, 2025
- Listing Date: December 15, 2025
What are The Objectives of Corona Remedies IPO?
This is the most critical point for investors to understand. The IPO is a 100% Offer for Sale. This means:
- The company, Corona Remedies, will not receive any proceeds from the public issue.
- The entire amount of ₹655.37 crores will go directly to the selling shareholders, primarily the promoters, who are monetizing a part of their investment.
How is The Financial Performance of Corona Remedies?
The following table summarizes the company's financial performance based on restated consolidated data.
(Amounts in ₹ Crores)
| Particulars | Period Ended 30 Jun 2025 | Year Ended 31 Mar 2025 | Year Ended 31 Mar 2024 | Year Ended 31 Mar 2023 |
Total Income | 348.56 | 1,202.35 | 1,020.93 | 891.10 |
Profit After Tax (PAT) | 46.20 | 149.43 | 90.50 | 84.93 |
EBITDA | 71.80 | 245.91 | 161.19 | 135.03 |
Net Worth | 607 | 606.3 | 480.4 | 408.5 |
Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
Source: RHP
Key Financial Observations:
Profit After Tax (PAT):
The company's PAT grew by an impressive 65% in FY25 to ₹149.43 Crores, reflecting strong operational leverage and a shift towards higher-margin products. This robust profit growth is a key driver of investor interest.
Total Income:
Revenue has grown consistently, crossing the ₹1,200 Crore mark in FY25. This growth is fueled by the company's strong brand presence in chronic therapies and its ranking as the second-fastest growing pharma company among the top 30 in India.
EBITDA:
Operational efficiency has improved significantly, with EBITDA margins expanding to over 20% in FY25. This indicates the company's ability to manage costs while scaling up its manufacturing capabilities.
Net Worth:
Net Worth has demonstrated robust growth, rising significantly to ₹606.3.Crore in FY 2025 from ₹480.4 Crore in FY 2024, underscoring the company's strengthening financial stability. This consistent increase reflects strong earnings retention, directly supporting the company's healthy Return on Net Worth (RoNW) of 24.65%.
Total Borrowings:
While total borrowings stood at ₹106.65 Crores as of June 2025, the company maintains a net cash positive position. This means its cash reserves exceed its debt, highlighting a very strong balance sheet.
Assets:
Total assets have grown steadily to over ₹1,000 Crores, driven by continuous capex in expanding manufacturing infrastructure. The significant increase in capital work-in-progress suggests future capacity additions are underway.
P/E Ratio & Peer Comparison
Based on its Fiscal Year 2025 earnings per share (EPS) of ₹24.43, the IPO is priced at a Price-to-Earnings (P/E) multiple of approximately 43.5x at the upper end of the price band (₹1062).
P/E Ratio = ₹1062 (Price) / ₹24.43 (Earnings Per Share)
P/E Ratio ≈ 43.5x
This valuation is right in line with the industry average, suggesting fair pricing.
| Company Name | P/E Ratio | Revenue (FY25, ₹ Cr) | RoNW (%) (FY25) |
Corona Remedies (at IPO price) | ~43.5x | 1,196.42 | 24.65% |
| Eris Lifesciences Ltd | 61.81x | 2,893.64 | 14.60% |
| Mankind Pharma Ltd | 45.77x | 12,207.44 | 13.89% |
| J.B. Chemicals & Pharma | 42.60x | 3,917.99 | 19.21% |
Industry Average | 43.74x | -- | -- |
Analysis for Investors:
Corona Remedies is priced almost exactly at the industry average P/E of 43.7x. However, its Return on Net Worth (RoNW) of 24.65% is significantly superior to peers like Eris Lifesciences, Mankind Pharma, and J.B. Chemicals. This indicates that Corona Remedies is generating higher returns for shareholders compared to its larger competitors, making the valuation look attractive despite being in line with the average.
Industry Outlook
The Indian pharmaceutical market (IPM) is a global powerhouse, known for its cost-effective manufacturing and strong domestic demand. The sector is shifting towards chronic therapies like cardiac and anti-diabetic drugs due to lifestyle changes. Corona Remedies is well-positioned in these high-growth segments. With a focus on branded formulations and a strong domestic presence, the company benefits from the structural tailwinds of the Indian healthcare sector, which is expected to grow steadily.
What Are The Strengths and Risks of Corona Remedies IPO?
Strengths:
- High Growth Profile: One of the fastest-growing pharma companies in India with a strong track record of revenue and profit growth.
- Strong Brands in Chronic Therapies: Focus on high-retention segments like women's health and cardio-diabetic care ensures steady revenue.
- Superior Financial Ratios: Best-in-class RoNW and improving margins demonstrate operational excellence.
- Net Cash Positive: A robust balance sheet with cash reserves exceeding debt provides financial stability.
Risks:
- 100% Offer for Sale (OFS): The IPO is purely an exit for promoters, with no funds coming into the company for growth.
- Regulatory Risks: The pharma industry is subject to stringent regulations and price controls (NLEM), which can impact margins.
- Intense Competition: The domestic formulation market is highly fragmented and competitive, with many large players vying for market share.
- Litigation: The company is involved in outstanding legal proceedings, which could pose a financial risk if outcomes are unfavorable.
What Are The Expert Recommendations – Should You Apply?
Subscribe
The Corona Remedies IPO offers a chance to invest in a high-quality, fast-growing pharma company at a fair price.
- For Value Investors: While the P/E isn't "cheap," the superior return ratios justify the valuation. It's a quality pick at a fair price.
- For Growth Investors: The company's consistent double-digit growth and focus on chronic therapies make it an attractive long-term bet.
- Our View: Despite the 100% OFS structure, the business fundamentals are very strong. The company is debt-light, profitable, and growing faster than the market. We recommend "Subscribe" for both potential listing gains and long-term holding.
Key Takeaways
- IPO Price Band: ₹1008 to ₹1062 per share
- Lot Size: 14 Shares (Minimum Investment: ₹14,868)
- Allotment & Listing Dates: Tentative listing on December 15, 2025.
- Recommendations of experts: A high-growth, financially robust pharma company offered at a fair valuation relative to its peers.
FAQs on Corona Remedies IPO
What is Corona Remedies IPO price band?
The price band for the IPO is set at ₹1008 to ₹1062 per equity share.
What is Corona Remedies IPO allotment date?
The allotment of shares is tentatively expected to be finalized on Thursday, December 11, 2025.
How to check Corona Remedies IPO allotment status?
You can check the allotment status on the website of the IPO registrar once the basis of allotment is finalized.
What is Corona Remedies IPO listing date?
The company's shares are tentatively scheduled to be listed on the BSE and NSE on Monday, December 15, 2025.
Should I apply for Corona Remedies IPO?
Yes, this is a recommended IPO. The company has demonstrated superior growth and profitability compared to many peers, has a strong balance sheet, and is priced fairly, making it an attractive investment opportunity.
IPO Disclaimer:
All IPO details provided are for informational purposes only and should not be considered investment advice. Investors are advised to review the official RHP/DRHP and consult a financial advisor before making any investment decisions.
